MX2021001877A - Composiciones y métodos para el tratamiento de lesión pulmonar aguda. - Google Patents

Composiciones y métodos para el tratamiento de lesión pulmonar aguda.

Info

Publication number
MX2021001877A
MX2021001877A MX2021001877A MX2021001877A MX2021001877A MX 2021001877 A MX2021001877 A MX 2021001877A MX 2021001877 A MX2021001877 A MX 2021001877A MX 2021001877 A MX2021001877 A MX 2021001877A MX 2021001877 A MX2021001877 A MX 2021001877A
Authority
MX
Mexico
Prior art keywords
treatment
lung injury
compositions
methods
acute lung
Prior art date
Application number
MX2021001877A
Other languages
English (en)
Spanish (es)
Inventor
Aron B Fisher
Sheldon I Feinstein
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2021001877A publication Critical patent/MX2021001877A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021001877A 2018-08-17 2019-08-15 Composiciones y métodos para el tratamiento de lesión pulmonar aguda. MX2021001877A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862719217P 2018-08-17 2018-08-17
PCT/US2019/046698 WO2020037146A1 (en) 2018-08-17 2019-08-15 Compositions and methods for treatment of acute lung injury

Publications (1)

Publication Number Publication Date
MX2021001877A true MX2021001877A (es) 2021-07-15

Family

ID=69524874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001877A MX2021001877A (es) 2018-08-17 2019-08-15 Composiciones y métodos para el tratamiento de lesión pulmonar aguda.

Country Status (11)

Country Link
US (2) US12070483B2 (cg-RX-API-DMAC7.html)
EP (1) EP3836953A4 (cg-RX-API-DMAC7.html)
JP (2) JP7483684B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210046698A (cg-RX-API-DMAC7.html)
CN (1) CN112703009B (cg-RX-API-DMAC7.html)
AU (1) AU2019321654B8 (cg-RX-API-DMAC7.html)
BR (1) BR112021002920A2 (cg-RX-API-DMAC7.html)
CA (1) CA3109798A1 (cg-RX-API-DMAC7.html)
IL (1) IL280868B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021001877A (cg-RX-API-DMAC7.html)
WO (1) WO2020037146A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112703009B (zh) 2018-08-17 2024-06-11 宾夕法尼亚大学董事会 治疗急性肺损伤的组合物和方法
KR20260034620A (ko) * 2023-05-05 2026-03-11 페록시테크 인코포레이티드. 패혈성 쇼크 치료용 조성물 및 방법
EP4720090A1 (en) * 2023-05-26 2026-04-08 The Trustees of The University of Pennsylvania Protective agent against endothelial dysfunction

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
CA2132012C (en) 1992-03-25 2003-04-22 John W. Shell Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
ATE302597T1 (de) 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
MXPA02007254A (es) 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
AU2001278864A1 (en) * 2000-06-30 2002-01-30 University Of Cincinnati Peptides with antioxidant and antimicrobial properties
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
WO2002096404A1 (en) 2001-05-29 2002-12-05 Depomed Development Ltd Method of treating gastroesophageal reflux disease and nocturnal acid breakthrough
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
EP1764095A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
WO2011157819A2 (en) * 2010-06-18 2011-12-22 Xiberscience Gmbh Peptides as active agents to stabilize biological barriers
US8962570B2 (en) * 2011-05-17 2015-02-24 University of Pittsburgh—of the Commonwealth System of Higher Education Therapeutic use of peptide inhibitors of NADPH oxidase; aerosolization as a delivery mechanism
US11110152B2 (en) * 2016-04-11 2021-09-07 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease
CN112703009B (zh) 2018-08-17 2024-06-11 宾夕法尼亚大学董事会 治疗急性肺损伤的组合物和方法

Also Published As

Publication number Publication date
JP7822065B2 (ja) 2026-03-02
US20250082715A1 (en) 2025-03-13
US20210315964A1 (en) 2021-10-14
BR112021002920A2 (pt) 2021-05-11
EP3836953A4 (en) 2022-06-29
EP3836953A1 (en) 2021-06-23
IL280868B1 (en) 2026-05-01
JP2024102207A (ja) 2024-07-30
AU2019321654A1 (en) 2021-03-18
JP2021534184A (ja) 2021-12-09
IL280868A (en) 2021-04-29
AU2019321654B1 (en) 2025-07-17
KR20210046698A (ko) 2021-04-28
US12070483B2 (en) 2024-08-27
AU2019321654B8 (en) 2025-08-07
JP7483684B2 (ja) 2024-05-15
WO2020037146A1 (en) 2020-02-20
CA3109798A1 (en) 2020-02-20
CN112703009B (zh) 2024-06-11
CN112703009A (zh) 2021-04-23

Similar Documents

Publication Publication Date Title
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1124013T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CY1123381T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1122184T1 (el) Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
CY1121473T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CL2022000531A1 (es) Composiciones y métodos para el tratamiento de infecciones virales.
CY1120373T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
MD3313423T2 (ro) Compoziții care conțin tulpini bacteriene de Blautia pentru tratamentul hipersensibilității viscerale
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
EP3651801B1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
EP3603636A4 (en) COMPOSITION TARGETING S1PR4 TO PREVENT OR TREAT NON-ALCOHOLIC STEATOHEPATITIS
EP3833340A4 (en) COMPOSITIONS AND METHODS OF TREATMENT FOR PRESBYOPIA
CY1124286T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
CO2019014647A2 (es) Composiciones inmunogénicas
EP3468555C0 (en) COMPOSITIONS FOR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
UY38352A (es) Inhibidores de integrina alfavbeta6
IL282041A (en) Egfr inhibitors for treating keratodermas
EP3709968C0 (de) Emulsionen zur behandlung von schleimhautinfektionen
MX392976B (es) Composiciones que comprenden cepas bacterianas.